Clinical Study Protocol

We are recognized as one of the leaders in designing EFSA compliant clinical study protocol design aiming to substantiate health claim or novel food authorizations.

Contact us

Related Resources

FoodChain ID and NOW Foods Partner to Showcase Regulatory Leadership

COMPANY NOW® Foods As a natural products leader, NOW’s dedication to superior quality at value prices has fueled its growth from a local health food store to a market leader…

How to create a compliant supplement label for Europe?

The labeling of a food supplement is highly regulated. The mandatory labeling information is listed in Directive 2002/46/EC. As it is also a foodstuff, the mandatory information laid down in…

What are the requirements for selling supplements online in Europe?

According to Article 14 of Regulation (EU) No. 1169/2011 of 25 October 2011 on the provision of food information to consumers (known as the FIC Regulation), the mandatory information required…

Novel foods and food supplements: understanding the European legal framework

A novel food is defined in Regulation (EU) 2015/2283 as a food for which human consumption was negligible in the European Union before 15 May 1997, when the first novel food regulation…

What are health claims?

A claim is any message or representation, not required by International or national legislation, including representation in the form of pictorial, graphic or symbolic matter in any form, which states, suggests or…

What are the Novel Foods ?

Regulation (EU) 2015/2283 of the European Parliament and of the Council of 25 November 2015 on novel foods, applicable since 1 January 2018, allows novel foods to be subject to simpler, clearer…

Service details

Following the evaluation of the strengths and weaknesses of the previously performed studies and EFSA opinions, we will design the relevant protocol which takes into consideration EFSA requested criteria for the evaluation of applications for authorization of health claims made on foods, including:

  • Specific procedures for human intervention studies (adequate control group, full randomization, treatment allocation concealed, power/ sample size calculation, etc.)
  • Appropriate dose for the recommended conditions of use (according to the labeling or project of labeling)
  • Relevance of inclusion/non-inclusion criteria for the study population in view of the target population for which the claim is intended
  • Biological and analytic validity of the surrogate markers of the claimed effect
  • Relevance of the main criteria of efficacy in view of the wording of the target claim
  • Adequacy of the intervention’s duration in view of the recommended conditions of use and the claimed effect
  • The scientific background relative to the study